1 / 40

TESTICULAR MALIGNANCIES

TESTICULAR MALIGNANCIES. Dr Imogen Patterson April 2010. Histologic classification. Germ cell tumours – 90-95% Seminoma Embryonal cell carcinoma Yolk sac tumour Choriocarcinoma Teratoma Non-germ cell tumours – 5-10%. Seminoma. Seminomas account for about 45% of GCT

shani
Télécharger la présentation

TESTICULAR MALIGNANCIES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TESTICULAR MALIGNANCIES Dr Imogen Patterson April 2010

  2. Histologic classification • Germ cell tumours – 90-95% • Seminoma • Embryonal cell carcinoma • Yolk sac tumour • Choriocarcinoma • Teratoma • Non-germ cell tumours – 5-10%

  3. Seminoma • Seminomas account for about 45% of GCT • Three subtypes of pure seminomas: • Classic • Anaplastic • spermatocytic

  4. Classical seminoma • Classic seminoma accounts for 80-85% of seminomas • Macroscopic: testicle usually enlarged, and when cut has a bulging homogeneous gray-white appearance • Microscopic: relatively large cells, with clear cytoplasm arranged in uniform sheets, lobules or columns • Supporting stroma shows varying amounts of lymphocytic infiltrate (20%) or granulomatous reaction • Occasional mitoses • Syncytiotrophoblastic elements occur in 10-20% and corresponds to the frequency of bHCG production

  5. Anaplastic seminoma • Also referred to seminoma with high mitotic index • Accounts for 5-10% of all seminomas • Several features suggest anaplastic seminoma is more aggressive and potentially more lethal • Greater mitotic activity (avg 3 mitoses/hpf) • Higher rate of local invasion • Increased rate of metastatic spread • Higher rate of bHCG production

  6. Spermatocytic seminoma • Accounts for <5% of all seminomas • Occur in men >40yrs (50% of pts are over 50yo) • approx 5% patients have bilateral disease • Macroscopic: tumours are large with yellowish, soft, mucoid appearance to the cut surface. • Microscopic: Cells vary in size and have deeply pigmented cytoplasm and closely resemble different phases of maturing spermatogonia • Nuclei have characteristic filamentous chromatin • Metastatic potential is low and once diagnosed via radical orchidectomy, no further treatment is required.

  7. Embryonal carcinoma • Pure EC comprises only 3-4% of GCT • EC cells present in variable amounts in up to 40% of mixed tumours • Most common in 3rd decade • EC elements have not been described in pre-pubertal testes • Macroscopic: small, round, irregular mass invading tunica vaginalis. • Cut surface appears greyish-white with areas of haemorrhage and necrosis • Microscopic: malignant appearing epithelioid cells arranged in glands or tubules • Cell borders are indistinct • Cytoplasm pale and vacuolated • Nuclei have see-through appearance with prominent nucleoli and numerous mitoses • Lymphovascular invasion and involvement of epididymal and paratesticular structure are common • Prognostic importance • Pure EC may be associated with elevated AFP • Syncytiotrophoblastic cells are scattered throughout the tumour and are responsible for bHCG elevation

  8. Yolk sac tumour • Predominant tumour in infants and children • In adults, pure yolk sac tumours account for a very small percentage – 2% • Present in up to 40% of mixed GCT • Responsible for the production of AFP in these tumours • Macroscopic: soft, homogeneous, grey-yellow and greasy. • Poorly encapsulated • Microscopically: at least 10 different patterns of yolk sac elements. • Epithelioid cells forming glands or ductal structures within a primitive mesenchymal stroma • Individual cells are small, varying shape, poorly defined borders • Vacuolated cytoplasm of glycogen and fat • Nuclei of varying sizes with frequent mitosis and prominent nucleoli

  9. Choriocarcinoma • Pure choriocarcinoma account for <1% of GCT • May present with distant metastasis and small intratesticular lesion • May present as palpable nodule, the size depends on extent of local haemorrhage • Macroscopic: cut surface may show central haemorrhage with viable, greyish-white tumour at the periphery • Microscopic: two cell types must be demonstrate to satisfy diagnosis of choriocarcinoma: • Syncytiotrophoblasts – large multinucleated cells, abundant + vacuolated cytoplasm, large hyperchromatic irregular nuclei • Produce bHCG • Cytotrophoblasts – closely packed, intermediate-sized, uniform cells with distinct cell border, clear cytoplasm, single vesicular nucleus

  10. Teratoma • Comprise 2-7% of adult tumours in pure form • 45-50% of mixed GCT contain teratoma • Contain more than one germ cell layer in various stages of maturation and differentiation • Mature elements resemble benign structures derived from normal ectoderm, endoderm, and mesoderm • Immature elements consist of undifferentiated primitive tissues from the three germ cell layers • Macroscopic: tumours are large, lobulated and nonhomogeneous in consistency • Cut surface: variably sized cysts containing gelatinous, mucinous or hyalinised material, interspersed with islands of solid tissue often containing cartilage or bone • Microscopic: cysts may be lined by squamous, cuboidal, columnar or transitional epithelium , solid element may contain anything! • Malignant changes may be recognised in such differentiated tissues, justifying the designation malignant teratoma

  11. Mixed tumours • Approx 60% of GCT contain >1 histologic pattern • Most frequent combination is EC, yolk sac, teratoma with syncytiotrophoblast cells, with or without seminoma • Pluripotential nature of GCT evident from the varied histologic patterns of metastasis • More than half display different morphologies in primary versus metastatic sites • 30-45% of patients dying with seminoma harbour nonseminomatous metastases • Converse rarely documented

  12. Intratubular germ cell neoplasia • Testicular carcinoma in situ (CIS) is widely regarded as the preinvasive precursor of all GCTs except spermatocytic seminoma • Early studies in infertile men and pts with testicular GCTs showed that 50% of men in whom CIS was found on biopsy developed “invasive” within 5 years if left untreated • ITGCN microscopic: large with abundant pale cytoplasm, irregularly outlined nuclei and located at the periphery of the seminiferous tubules between normal appearing sertoli cells • Well studied in Scandinavian studies – reported incidence is 0.8% • Corresponds to lifetime risk of developing invasive testis ca in this population • Groups of patients at risk for development of CIS: • History of contralateral testicular cancer: 5-6% • Cryptorchidism: 3-5% • An atrophic contralateral testis with unilateral testis cancer: 30% • Extragonadal germ cell tumour: 40% • Intersex or sexual ambiguity: 25-100%

  13. ITGCN • Open testicular biopsy remains gold standard for diagnosing CIS • Management depends on: • Patient age • Bilateral or unilateral CIS • Associated testicular atrophy • Physician philosophy • Treatment options include: • Observation • Radiation • Chemotherapy • orchidectomy

  14. Epidemiology • 2008: 8000 new testis cancer cases in US • 370 deaths • Most common solid organ tumour in men aged 20-34 • Second most common tumour in men aged 35-40 • Lifetime probability of developing testicular cancer is 1 in 300 and risk of dying is 1 in 5000 • Age-adjusted incidence is highest in Scandinavian countries (9.3 cases per 100,000men) • Intermediate in USA: 5.4 per 100,000 men • Lowest in Africa and Asia: 0.9 per 100,000 men

  15. Other factors • Racial factors: • Incidence of testicular tumours in American blacks is approx 1/3 that in American whites, but 10 times that of African blacks • In Israel, Jewish people have 8x higher incidence than non-Jewish • Higher incidence in upper and middle socioeconomic classes of whites in LA • Genetic factors: • Relatively higher incidence of testicular tumours in twins, brothers and family members but not overwhelming • Laterality and bilaterality: • Slightly more common in right than left • 2-3% are bilateral • Synchronous 17-30% • Metachronous 70-83%

  16. Risk factors • Cryptorchidism – 3-14x • Metachronous testis cancer – 2-4x • Positive family history – 5x • Diethylstilbestrol exposure – 2.5-5x • Gonadal dysgenesis – 50x • Androgen insensitivity syndrome – 15x

  17. Patterns of spread • GCT spreads in predictable and stepwise fashion, except choriocarcinoma • Primary landing zone for right-sided testicular tumours is interaortocaval region beneath left renal vein, then paracaval and preaortic region • In many cases, lymphatic drainage crossed from right to left • Primary landing zone for left testicular malignancies is para-aortic region bounded by left ureter, left renal vein , aorta and IMA origin • Subsequent cephalad drainage is to cysterna chyli, thoracic duct, and supraclavicular nodes • Lymphatics of epididymis drain into the external iliac chain, affording locally extensive tumours access to pelvic LN • Inguinal LN metastasis may result from scrotal involvement or retrograde lymphatic spread, or prior scrotal or inguinal surgery or massive retroperitoneal deposits • Extranodal distal metastasis results from direct vascular invasion or tumour emboli • Despite surgical excision of negative RP LN, distant failure rate is around 5%

  18. Presentation • Usual presentation is of a nodule of painless swelling of one gonad • 10% of patients may present due to metastases • Neck mass • Respiratory symptoms • GIT disturbances • Lumbar back pain • Bone pain • Peripheral nervous system manifestations

  19. Tumour markers • GCT markers belong to two main classes: • Oncofoetal substances – AFP and bHCG • Cellular enzymes – LDH and PLAP

  20. AFP • 70kDalton single chain glycoprotein • Predominant serum-binding protein in foetus • Synthesized in foetal yolk sac, liver and intestine • Peak gestational levels are between weeks 12-14 • Gradually decline after birth • Serum half life is 5-7 days • AFP may be produced by: • Pure EC • Teratocarcinoma • Yolk sac tumour • Combined tumours • AFP levels are normal in pure seminoma and pure choriocarcinoma

  21. bHCG • 38kDalton protein secreted by placental syncytiotrophoblasts to maintain viability of corpus luteum • Two subunits of HCG • aHCG: homologous with pituitary glycoprotein hormones (LH, FSH, TSH) • bHCG: 70% homologous with LH beta chain • Serum half life bHCG: 24-36hrs • Can be falsely elevated in some conditions

  22. LDH • 134 kDalton cellular enzyme produced by muscles, liver and numerous other organs • Elevation is non-specific, but evidence suggests it can be used as a marker of tumour volume or advanced disease

  23. PLAP and GGTP • Placental alkaline phosphatase – a foetal isoenzyme • Elevated in 40% of patients with advanced disease • Gamma-glutamyl-transpepidase – a hepatocellular enzyme frequently elevated in benign or malignant diseases of the liver

  24. Clinical applications of tumour markers • Among patients with NSGCT: • 50-70% have elevated AFP • 40-60% have elevates bHCG • 90% patients have elevations of one or both • Additionally, 10-15% of patients with advanced disease can have normal tumour markers • Normalisation of markers after treatment do not exclude the presence of residual disease • 10-20% of patients undergoing chemotherapy and then RPLND have viable tumour despite normal tumour markers

  25. Radiographic studies • Scrotal USS – extension of physical examination • Any hypoechoic area within tunica albuginea is markedly suspicious for testicular cancer • CXR – in clinical stage I disease, risk of chest involvement is <5% • CT – most effective means to identify RPLN • Cannot distinguish benign lesions (fibrosis) from teratoma • Unable to detect micrometastases • Understages disease • MRI – no distinct advantage over CT

  26. PET • PET has a limited role in staging and evaluation of patients with metastatic disease • Can detect malignant cells, but cannot distinguish between teratoma and fibrosis • PET therefore not recommended in NSGCT • PET scan however is highly predictive for residual tumour following chemotherapy in patients with stage II or III seminoma • Helps clarify which patients may benefit from RPLND

  27. PET scan

  28. Staging system

  29. Prognostic classification system

  30. Treatment of primary tumour • Radical orchidectomy – inguinal exploration and en bloc removal of testis, tunica albuginea and spermatic cord • Partial orchidectomy – may be attempted in special cases (bilateral tumour or solitary testis) • Post orchidectomy tumour markers – presence of elevated tumour markers 3 weeks post orchidectomy may indicate presence of metastatic disease • Treatment of scrotal violation • May be present if pT4 tumour, previous scrotal surgery, or previous inguinal surgery • After trans-scrotal bx – radical inguinal orchidectomy, excision of ipsilateral hemiscrotum including scar • Follow up with examination of inguinal lymph nodes

  31. Treatment: Seminoma Stage I • Surveillance • Rationale: over 80% with clinical stage N0 will have pathological stage N0 • Disadvantages: higher relapse rate than treatment • Strict compliance and intensive follow up required • Patients may have more psychological stress • Indicated for compliant stage I with normal post-orchidectomy markers • Relapse appears more likely for tumours>4-6cm, rete testis invasion and age> 34yrs • Usually occurs in RP • 20% are more than four years post orchidectomy • Radiation • Rationale: very low morbidity and mortality • Disadvantages: increases risk of death (2x) from cardiac disease and secondary malignancy starting at 15 yrs post XRT • Relapses occur outside RP – treat with chemo • 5 year OS >95% • Chemotherapy • Rationale: may have lower mortality than XRT • Disadvantages: myelosuppression, nausea, fatigue • 1-2 cycles of AUC 7 carboplatin appear to be as effective as XRT • Relapses occur in RP

  32. Seminoma stage IIa and IIb • Traditionally, seminoma patients with bulky RP disease received XRT • More recently, adjuvant chemotherapy has been preferred • XRT – ipsilateral external iliac, bilateral common iliac, paracaval and paraaortic nodes, including cysterna chyli • N1 disease: 30Gy • N2 disease: 35Gy • BEP x 3

  33. Seminoma stage IIc and III • Cisplatin-based chemo has been found to be highly effective against disseminated testicular seminoma (as well as nonseminomatous tumours) • More than 90% of patients who present with stage III disease achieve complete response to chemotherapy alone • More than 90% of responders remain disease free during follow up of 4 years • Response rates seen better if no prior XRT is given • Management of post chemo residual mass • RPLND for seminoma is difficult as seminoma involves the RP in a fibrotic process that is similar to RPF • In most patients explored after chemotherapy, only residual necrosis or fibrosis is found

  34. Treatment: Nonseminoma Stage I • Surveillance • Rationale: 70% of clinical stage N0 have pathologic N0 • Disadvantages: has higher relapse rate than treatment • Strict compliance and intensive follow up are required • Relapse more likely when: • Lymphatic invasion, vascular invasion, stage pT2 or higher, predominance of EC, absence of yolk sac • Indicated for compliant stage I men • 60% relapses in RP, 40% outside RP • 80% develop within 1 year • RPLND • Rationale: treats RP metastases, permits more accurate staging, requires less intensive follow up. • CT understages around 25% of stage I disease • Disadvantages: invasive, may treat up to 70% unnecessarily, can cause ejaculatory dysfunction etc • Indicated for stage I men with normal post-orchidectomy tumour markers • Relapses occur in 10% of men who are pN0, usually outside RP • Treat with chemotherapy • Chemotherapy • Rationale: treats metastases inside and outside RP, less invasive than RPLND, requires less intensive surveillance and lower relapse rate than RPLND or surveillance • Disadvantage: treats 70% unnecessarily and will not adequately treat teratoma • Usually consists in this setting of 2 cycles of BEP • Relapses in RP, usually containing teratoma and should be treated with RPLND or salvage chemo

  35. Low volume metastatic NSGCT • Option of RPLND or primary chemotherapy • Similarly effective for Stage II disease • Chemotherapy consists of 3 or 4 cycles of BEP

  36. Stage IIc and III NSGCT • Divided into good prognosis and poor prognosis • Good prognosis patients receive standard chemotherapy regimens (3 x BEP) • Poor prognosis patients should start chemotherapy quickly – 4 x BEP • Majority achieve durable complete remission • 20-30% relapse or fail to achieve complete response and eventually die • Salvage chemo indicated for men who progress on primary chemo or who relapse • VIP x 4 • 50% obtain complete response • Post chemotherapy residual mass • 45-50% contain teratoma after primary chemotherapy for NSGCT

  37. Non germ cell tumours • Leydig cell tumours • 1-3% of all testicular tumours and most common of non-germ cell tumours • Patients generally aged between 20 and 60 • 20% of Leydig tumours that occur in prepubertal patients are considered benign • Aetiology unknown • Macroscopically: small, yellow to brown and well circumscribed • Histology: eosinophilic cells, extracellular Reinke’s crystals • May produce testosterone and 17-ketosteroid, therefore may present with virilisation or gynaecomastia or low libido • Sertoli cell tumours • <1% testicular tumours • Generally present before age 20 and up to 1/3 have gynaecomastia • Large-cell calcifying type occurs most commonly in paediatric population and can be associated with Peutz Jeghers syndrome or Carney syndrome • 10% of these tumours are malignant, only reliable indicator is presence of metastasis • Gonadoblastoma • Occur almost exclusively in patients with intersex disorder (complete androgen insensitivity, male pseudohermaphroditism and Turner syndrome) and gonadal dysgenesis (45x, 46XY) • Less than 0.5% all testicular tumours • 80% patients are phenotypically female

  38. Other tumours • Lymphoma • Can occur as primary tumour or recurrence • Most common testicular neoplasm in patients >60yrs • Metachronous or synchronous development in 38% • Diffuse painless enlargement of testis • 30% patients have systemic constitutional symptoms including weight loss, anorexia or fever • Prognosis is poor: 50% 5 year survival • Leukaemia • Common site of recurrence, mainly in children (ALL) • Bilateral involvement occurs in 50% • Biopsy is diagnostic • Treated with testicular irradiation and chemotherapy • Metastatic tumours • Rare, but include prostate, lung, GIT, melanoma and kidney

More Related